• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A phase I randomized controlled trial to evaluate safety and clinical effect of topically applied GSK2981278 ointment in a psoriasis plaque test.

作者信息

Kang E G, Wu S, Gupta A, von Mackensen Y-L, Siemetzki H, Freudenberg J M, Wigger-Alberti W, Yamaguchi Y

机构信息

GlaxoSmithKline, Collegeville, 1250 S. Collegeville Rd, Collegeville, PA, 19426, U.S.A.

bioskin GmbH, Burchardstrasse 17, Hamburg, 20095, Germany.

出版信息

Br J Dermatol. 2018 Jun;178(6):1427-1429. doi: 10.1111/bjd.16131. Epub 2018 Mar 23.

DOI:10.1111/bjd.16131
PMID:29150844
Abstract
摘要

相似文献

1
A phase I randomized controlled trial to evaluate safety and clinical effect of topically applied GSK2981278 ointment in a psoriasis plaque test.一项I期随机对照试验，以评估局部应用GSK2981278软膏在银屑病斑块试验中的安全性和临床效果。
Br J Dermatol. 2018 Jun;178(6):1427-1429. doi: 10.1111/bjd.16131. Epub 2018 Mar 23.
2
Calcipotriene ointment applied once a day for psoriasis: a double-blind, multicenter, placebo-controlled study.卡泊三醇软膏每日一次用于治疗银屑病：一项双盲、多中心、安慰剂对照研究。
Arch Dermatol. 1996 Dec;132(12):1527.
3
An investigator-initiated, double-blind, vehicle-controlled pilot study: assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasis.一项研究者发起的、双盲、赋形剂对照的初步研究：评估局部封包卤倍他索 0.05%软膏治疗银屑病的快速耐受情况。
J Am Acad Dermatol. 2014 Nov;71(5):954-959.e1. doi: 10.1016/j.jaad.2014.05.040. Epub 2014 Jun 11.
4
Comparison of indirubin concentrations in indigo naturalis ointment for psoriasis treatment: a randomized, double-blind, dosage-controlled trial.比较治疗银屑病的青黛膏中靛玉红的浓度：一项随机、双盲、剂量对照试验。
Br J Dermatol. 2018 Jan;178(1):124-131. doi: 10.1111/bjd.15894. Epub 2017 Dec 14.
5
Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis.卡泊三醇（MC 903）软膏与氟轻松软膏治疗银屑病的对比研究。
J Am Acad Dermatol. 1994 Nov;31(5 Pt 1):755-9. doi: 10.1016/s0190-9622(94)70237-3.
6
Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas.骨化三醇3μg g⁻¹软膏与卡泊三醇50μg g⁻¹软膏对局限于面部、发际线、耳后或屈侧部位的慢性斑块状银屑病皮肤安全性和疗效的个体内比较。
Br J Dermatol. 2003 Feb;148(2):326-33. doi: 10.1046/j.1365-2133.2003.05228.x.
7
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.巴瑞替尼治疗中重度银屑病的随机 2b 期临床试验。
Br J Dermatol. 2016 Jun;174(6):1266-76. doi: 10.1111/bjd.14403. Epub 2016 Apr 5.
8
Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.卡泊三醇 0.005% 泡沫剂治疗斑块状银屑病的疗效和安全性：两项多中心、随机、双盲、对照、III 期临床试验结果。
Am J Clin Dermatol. 2012 Aug 1;13(4):261-71. doi: 10.2165/11630710-000000000-00000.
9
Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator.外用马沙骨化醇治疗寻常型银屑病：一项设有活性对照的安慰剂对照、双盲、剂量探索研究。
Br J Dermatol. 1999 Aug;141(2):274-8. doi: 10.1046/j.1365-2133.1999.02975.x.
10
Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.骨化三醇3微克/克软膏治疗轻至中度斑块型银屑病：两项安慰剂对照、多中心、随机双盲临床研究结果
J Drugs Dermatol. 2007 Apr;6(4):428-35.

引用本文的文献

1
Emerging Therapeutic Targets in Rheumatoid Arthritis: Focusing on HIF-1α, Nrf2, STATs, and RORγt.类风湿关节炎中新出现的治疗靶点：聚焦于缺氧诱导因子-1α、核因子E2相关因子2、信号转导和转录激活因子以及维甲酸相关孤儿受体γt
Curr Drug Targets. 2025;26(8):507-533. doi: 10.2174/0113894501372670250408074908.
2
Unveiling Psoriasis: Delving into Pathogenesis, Treatment Breakthroughs, and Patent Trends.揭开银屑病的面纱：深入探讨发病机制、治疗突破及专利趋势。
Recent Adv Inflamm Allergy Drug Discov. 2025;19(1):31-45. doi: 10.2174/0127722708307214240628042627.
3
New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis.
用于银屑病的新型及新兴口服/局部小分子治疗方法。
Pharmaceutics. 2024 Feb 6;16(2):239. doi: 10.3390/pharmaceutics16020239.
4
Molecular components of the circadian clock regulate HIV-1 replication.生物钟的分子成分调节HIV-1复制。
iScience. 2023 May 29;26(7):107007. doi: 10.1016/j.isci.2023.107007. eCollection 2023 Jul 21.
5
Small molecule inhibitors of RORγt for Th17 regulation in inflammatory and autoimmune diseases.用于炎症和自身免疫性疾病中Th17调节的RORγt小分子抑制剂。
J Pharm Anal. 2023 Jun;13(6):545-562. doi: 10.1016/j.jpha.2023.05.009. Epub 2023 May 20.
6
Macrocyclic Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonists.大环维甲酸受体相关孤儿受体C2反向激动剂
ACS Med Chem Lett. 2023 Jan 18;14(2):191-198. doi: 10.1021/acsmedchemlett.2c00500. eCollection 2023 Feb 9.
7
New Topical Therapies for Psoriasis.治疗银屑病的新型局部治疗药物。
Am J Clin Dermatol. 2022 Jan;23(1):13-24. doi: 10.1007/s40257-021-00649-w. Epub 2021 Oct 27.
8
Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis.发现一种新型 RORγ 拮抗剂，具有皮肤局限暴露，用于轻度至中度银屑病的局部治疗。
Sci Rep. 2021 Apr 28;11(1):9132. doi: 10.1038/s41598-021-88492-1.
9
A Functional Variant rs3093023 in Is Associated With IgA Nephropathy by Regulating Th17 Cells in a North Han Chinese Population.一个位于 的功能性变异 rs3093023 通过调节中国北方汉族人群中的 Th17 细胞与 IgA 肾病相关。
Front Immunol. 2021 Feb 25;12:600598. doi: 10.3389/fimmu.2021.600598. eCollection 2021.
10
Gut microbiota from patients with arteriosclerotic CSVD induces higher IL-17A production in neutrophils via activating RORγt.动脉粥样硬化性 CSVD 患者的肠道微生物群通过激活 RORγt 诱导中性粒细胞产生更高水平的 IL-17A。
Sci Adv. 2021 Jan 22;7(4). doi: 10.1126/sciadv.abe4827. Print 2021 Jan.